NCT03375034View on ClinicalTrials.gov

Exploring the Role of the GABAergic Modulation in Pain Transmission in Human

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

December 28, 2017

Study Completion Date

January 31, 2018

Conditions
Neuropathic Pain
Interventions
DRUG

NDMC 20mg

Oral administration of one NDMC 20mg capsule and two Placebo capsules

DRUG

NDMC60mg

Oral administration of three NDMC 20mg capsules

DRUG

Clonazepam 1.5mg

Oral administration of three clonazepam 0.5mg capsules

DRUG

Placebo

Oral administration of three Placebo capsules

Trial Locations (1)

1211

UGeneva, Geneva

All Listed Sponsors
lead

Jules Desmeules

OTHER

NCT03375034 - Exploring the Role of the GABAergic Modulation in Pain Transmission in Human | Biotech Hunter | Biotech Hunter